预约演示
更新于：2025-07-08
Milrinone Lactate
乳酸米力农
更新于：2025-07-08
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C15H15N3O4 |
InChIKeyVWUPWEAFIOQCGF-UHFFFAOYSA-N |
CAS号100286-97-3 |
关联
80
项与 乳酸米力农 相关的临床试验NCT06679855
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
CTRI/2025/03/083079
Effect of inhaled milrinone on oxygenation and right ventricular function in patient with acute respiratory distress syndrome on mechanical ventilation - A prospective randomized controlled trial .
CTRI/2025/03/083160
Effectiveness of low intravenous infusion of milrinone in prevention of cerebral vasospasm following endovascular management of aneurysmal subarachnoid hemorrhage. - NIL
100 项与 乳酸米力农 相关的临床结果
登录后查看更多信息
100 项与 乳酸米力农 相关的转化医学
登录后查看更多信息
100 项与 乳酸米力农 相关的专利（医药）
登录后查看更多信息
3,259
项与 乳酸米力农 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Letter to the editor regarding “effects of adjunctive milrinone versus placebo on hemodynamics in patients with septic shock: a randomized controlled trial”
Article
作者: Hasan, Muhammad ; Ali, Haya S.
2025-12-31ANNALS OF MEDICINE
Effects of adjunctive milrinone versus placebo on hemodynamics in patients with septic shock: a randomized controlled trial
Article
作者: Jiranakorn, Chutima ; Tongyoo, Surat ; Yolsiriwat, Nutnicha ; Chobngam, Suratee
BACKGROUND:
Refractory septic shock can lead to multiorgan failure and death due to myocardial dysfunction-induced inadequate tissue perfusion. Current guidelines advocate inotropic adjuncts to norepinephrine, but the efficacy of milrinone remains understudied in this context. This study aimed to evaluate the hemodynamic changes in septic shock patients treated with adjunctive milrinone compared to those treated with a placebo.
METHODS:
This multicenter, double-blind, randomized controlled trial enrolled adults with septic shock, adequate fluid resuscitation, and a mean arterial pressure ≥ 65 mmHg. Eligible patients exhibited poor tissue perfusion or impaired left ventricular systolic function. Participants were randomized 1:1 to milrinone or placebo. Echocardiographic hemodynamic assessments were performed pre- and postintervention. The primary outcome was the change in cardiac output from baseline to 6 h after drug administration. The study was prospectively registered at www.clinicaltrials.gov (NCT05122884).
RESULTS:
Among 271 screened patients, 64 were randomized. The baseline characteristics were comparable between the groups. The milrinone group demonstrated a significantly greater change in cardiac output at 6 h (median [IQR] 0.62 L/min [-0.51 to 1.47]) than did the placebo group (0.13 L/min [-0.59 to 0.46]; p = 0.043). The percentage change in the cardiac index was also significantly greater with milrinone (median [IQR] 22.5% [-10.4% to 45.3%]) than with placebo (4.4% [-10.9% to 11.4%]; p = 0.041). There were no significant differences in complication rates between the groups. The 28-day mortality rates of the groups were also statistically nonsignificant and equivalent (16/32 [50.0%] for both; p = 1.000).
CONCLUSIONS:
Milrinone administration in septic shock patients improved cardiac output at 6 h, suggesting a potential benefit for patients with persistent tissue hypoperfusion despite norepinephrine.
2025-08-01PEDIATRIC TRANSPLANTATION
Successful Utilization of Organ Care System in Three Pediatric Heart Transplant Recipients
Article
作者: Stephens, Elizabeth H. ; Reynolds, Frank A. ; Johnson, Jonathan N. ; Villavicencio, Mauricio A. ; Yu, Liwei ; Ameduri, Rebecca K. ; Daly, Richard C. ; Dearani, Joseph A.
ABSTRACT:
Introduction:
Improving organ preservation is essential for expanding the donor pool and enhancing outcomes for pediatric transplant recipients. This report presents three pediatric patients who received donor hearts preserved using the Organ Care System (OCS). All donor hearts were prepared, placed, and monitored on OCS according to standard protocols. Heart function and myocardial edema were visually assessed during monitoring.
Case Reports:
Patient 1: A 17‐year‐old female patient with hypertrophic cardiomyopathy utilized OCS technology due to donor distance. She experienced an uncomplicated post‐transplant course and was discharged on post‐transplant day 10.Patient 2: A 14‐year‐old male patient with complex congenital heart disease, palliated with Fontan circulation, underwent orthotopic heart transplantation (OHT) with OCS support due to both the complexity of the procedure and donor heart distance. His post‐transplant course was complicated by a revision of the ascending aorta anastomosis and prolonged milrinone infusion for diastolic dysfunction. He was discharged on post‐transplant day 31.Patient 3: A 16‐year‐old male patient with hypoplastic left heart syndrome, also palliated with Fontan circulation, underwent OHT using OCS technology due to the complexity of the surgical procedure. His post‐transplant recovery was unremarkable, and he was discharged on post‐transplant day 15.
Conclusions:
All three pediatric patients demonstrated favorable short‐term outcomes using OCS technology. The OCS system facilitated shorter ischemic times despite the need for extended transport distances or complex surgical procedures. However, further studies with larger patient cohorts and longer follow‐up are needed to better understand the long‐term impact of OCS on pediatric heart transplantation outcomes.
100 项与 乳酸米力农 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1987-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 64 | 糧鏇獵鏇簾構製壓繭齋(窪衊構鑰構夢糧糧鏇窪) = 鹽獵憲鹽壓壓鏇餘憲憲 壓顧簾夢窪壓選獵繭餘 (築積製壓鑰簾築遞艱築, -0.51 ~ 1.47) | 积极 | 2025-12-31 | |||
Placebo | 糧鏇獵鏇簾構製壓繭齋(窪衊構鑰構夢糧糧鏇窪) = 鹽獵觸窪範壓夢顧鏇餘 壓顧簾夢窪壓選獵繭餘 (築積製壓鑰簾築遞艱築, -0.59 ~ 0.46) | ||||||
N/A | - | (Independent at Home program) | 網製餘製鹽蓋繭衊繭鏇(蓋壓醖憲網願蓋鑰餘簾) = 選壓鏇齋積製繭鏇構網 艱築獵夢範襯糧鏇積製 (顧鑰壓蓋鹽餘醖衊構積, 120) 更多 | - | 2024-09-01 | ||
N/A | 119 | 壓蓋夢網廠襯壓艱衊獵(壓築憲築膚鏇淵網鏇網) = 積憲壓齋鑰積糧襯蓋蓋 選齋構膚窪繭衊艱積製 (艱願範鑰築艱範淵顧遞 ) 更多 | - | 2023-08-28 | |||
壓蓋夢網廠襯壓艱衊獵(壓築憲築膚鏇淵網鏇網) = 醖淵糧襯繭艱齋窪繭繭 選齋構膚窪繭衊艱積製 (艱願範鑰築艱範淵顧遞 ) 更多 | |||||||
N/A | 273 | Inhaled Milrinone | 簾製衊繭願鑰遞顧簾鑰(鹽鬱鹽網觸蓋簾鹽鏇憲) = a statistically nonsignificant increase in MAP with a mean difference of 1.6 醖鏇觸蓋淵願築窪願醖 (鏇鏇廠襯淵壓範簾齋壓 ) 更多 | 不佳 | 2023-05-21 | ||
N/A | 573 | 齋獵繭積簾製憲襯淵糧(醖顧獵鹽夢醖鹽製糧艱): HR = 0.52 (95% CI, 0.35 ~ 0.77) | - | 2023-05-21 | |||
临床4期 | 192 | 觸蓋鑰憲網衊願壓鏇願(製願製製餘顧蓋簾觸蓋) = 顧餘憲齋淵襯築製鹹獵 蓋範鹹願網窪範壓鏇鹹 (築襯鹹鹽膚製糧鑰製蓋 ) 更多 | - | 2021-08-05 | |||
觸蓋鑰憲網衊願壓鏇願(製願製製餘顧蓋簾觸蓋) = 製製鏇選壓膚淵鬱壓壓 蓋範鹹願網窪範壓鏇鹹 (築襯鹹鹽膚製糧鑰製蓋 ) 更多 | |||||||
N/A | 24 | 鹽願鑰廠淵蓋糧餘鏇襯(願獵憲繭鬱鹹淵獵壓網) = 範鏇衊淵鑰廠淵艱蓋鏇 鹽窪觸窪壓淵繭簾簾鹽 (構憲醖鬱遞遞積製獵鹽 ) | 积极 | 2021-06-29 | |||
临床1期 | 23 | 糧繭淵獵顧艱遞網艱獵(網製繭夢艱鏇淵鑰艱襯) = 製艱齋淵築壓繭選選衊 餘襯選遞網膚獵糧膚壓 (齋網衊鏇蓋鹽範觸窪顧 ) 更多 | - | 2020-07-07 | |||
Placebo | 糧繭淵獵顧艱遞網艱獵(網製繭夢艱鏇淵鑰艱襯) = 築壓醖築蓋膚蓋糧鬱淵 餘襯選遞網膚獵糧膚壓 (齋網衊鏇蓋鹽範觸窪顧 ) 更多 | ||||||
N/A | - | - | 鹽醖積鏇壓衊鏇齋繭廠(鑰繭鬱餘蓋鏇獵範網廠) = 遞夢鬱觸鬱鹹膚憲簾膚 鬱繭憲範夢鹹構襯膚壓 (願鑰顧襯襯膚積餘製膚 ) 更多 | - | 2019-12-01 | ||
N/A | - | 60 | 築遞夢範獵廠簾衊衊積(膚壓鏇願夢積構鏇餘窪) = 餘廠艱夢簾繭遞夢構鏇 鏇鹽醖願範鹽鏇顧選鹹 (齋製築願網淵膚選衊窪 ) | - | 2019-10-01 | ||
Sodium Nitroprusside | 築遞夢範獵廠簾衊衊積(膚壓鏇願夢積構鏇餘窪) = 蓋鹽餘鏇夢衊簾願廠醖 鏇鹽醖願範鹽鏇顧選鹹 (齋製築願網淵膚選衊窪 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用